Evotec SE EVOTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVOTF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $14.41
- Day Range
- $13.83–13.93
- 52-Week Range
- $13.83–25.48
- Bid/Ask
- $14.16 / $15.17
- Market Cap
- $2.45 Bil
- Volume/Avg
- 200 / 6,391
Key Statistics
- Price/Earnings (Normalized)
- 27.93
- Price/Sales
- 2.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 5,086
- Website
- https://www.evotec.com
Competitors
Valuation
|
Metric
|
EVOTF
|
CTLT
|
LONN
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.93 | 100.11 | 33.38 |
Price/Book Value | 2.03 | 2.79 | 4.08 |
Price/Sales | 2.79 | 2.53 | 5.87 |
Price/Cash Flow | 72.10 | 55.34 | 29.64 |
Price/Earnings
EVOTF
CTLT
LONN
Financial Strength
|
Metric
|
EVOTF
|
CTLT
|
LONN
|
|---|---|---|---|
Quick Ratio | 1.93 | 1.54 | 1.12 |
Current Ratio | 2.16 | 2.48 | 1.77 |
Interest Coverage | −6.83 | −5.23 | 9.00 |
Quick Ratio
EVOTF
CTLT
LONN
Profitability
|
Metric
|
EVOTF
|
CTLT
|
LONN
|
|---|---|---|---|
Return on Assets (Normalized) | −4.21% | −2.51% | 5.28% |
Return on Equity (Normalized) | −8.08% | −6.08% | 9.02% |
Return on Invested Capital (Normalized) | −5.57% | −0.60% | 7.29% |
Return on Assets
EVOTF
CTLT
LONN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Pwnzjpbgs | Ppcrmr | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Qxbqqkwc | Ykmpv | $68.4 Bil | |
HLN
| Haleon PLC ADR | Ddvmcbny | Vdcgl | $36.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Rqfxcrfgs | Kyjr | $14.9 Bil | |
VTRS
| Viatris Inc | Ndhkprw | Mfrpm | $13.9 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Fmxwnzhk | Hvnr | $12.0 Bil | |
CTLT
| Catalent Inc | Gmgxbfgvx | Vzzkfd | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Cscdqyq | Lsvbv | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Xsfcqvfv | Clp | $3.9 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Djbnpdwky | Trnbsbn | $3.4 Bil |